Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA.

Gu L, Lingeman R, Yakushijin F, Sun E, Cui Q, Chao J, Hu W, Li H, Hickey RJ, Stark JM, Yuan YC, Chen Y, Vonderfecht SL, Synold TW, Shi Y, Reckamp KL, Horne D, Malkas LH.

Clin Cancer Res. 2018 Dec 1;24(23):6053-6065. doi: 10.1158/1078-0432.CCR-18-0592. Epub 2018 Jul 2.

PMID:
29967249
2.

How Does the Proliferating Cell Nuclear Antigen Modulate Binding Specificity to Multiple Partner Proteins?

Li H, Sandhu M, Malkas LH, Hickey RJ, Vaidehi N.

J Chem Inf Model. 2017 Dec 26;57(12):3011-3021. doi: 10.1021/acs.jcim.7b00171. Epub 2017 Nov 17.

PMID:
29095607
3.

Partial Purification of a Megadalton DNA Replication Complex by Free Flow Electrophoresis.

Li CM, Miao Y, Lingeman RG, Hickey RJ, Malkas LH.

PLoS One. 2016 Dec 30;11(12):e0169259. doi: 10.1371/journal.pone.0169259. eCollection 2016.

4.

Validating the disruption of proliferating cell nuclear antigen interactions in the development of targeted cancer therapeutics.

Smith SJ, Hickey RJ, Malkas LH.

Cancer Biol Ther. 2016;17(3):310-9. doi: 10.1080/15384047.2016.1139247. Epub 2016 Feb 18.

5.

The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma Cells.

Gu L, Chu P, Lingeman R, McDaniel H, Kechichian S, Hickey RJ, Liu Z, Yuan YC, Sandoval JA, Fields GB, Malkas LH.

EBioMedicine. 2015 Nov 10;2(12):1923-31. doi: 10.1016/j.ebiom.2015.11.016. eCollection 2015 Dec.

6.

Comparison of RNA-seq and microarray-based models for clinical endpoint prediction.

Zhang W, Yu Y, Hertwig F, Thierry-Mieg J, Zhang W, Thierry-Mieg D, Wang J, Furlanello C, Devanarayan V, Cheng J, Deng Y, Hero B, Hong H, Jia M, Li L, Lin SM, Nikolsky Y, Oberthuer A, Qing T, Su Z, Volland R, Wang C, Wang MD, Ai J, Albanese D, Asgharzadeh S, Avigad S, Bao W, Bessarabova M, Brilliant MH, Brors B, Chierici M, Chu TM, Zhang J, Grundy RG, He MM, Hebbring S, Kaufman HL, Lababidi S, Lancashire LJ, Li Y, Lu XX, Luo H, Ma X, Ning B, Noguera R, Peifer M, Phan JH, Roels F, Rosswog C, Shao S, Shen J, Theissen J, Tonini GP, Vandesompele J, Wu PY, Xiao W, Xu J, Xu W, Xuan J, Yang Y, Ye Z, Dong Z, Zhang KK, Yin Y, Zhao C, Zheng Y, Wolfinger RD, Shi T, Malkas LH, Berthold F, Wang J, Tong W, Shi L, Peng Z, Fischer M.

Genome Biol. 2015 Jun 25;16:133. doi: 10.1186/s13059-015-0694-1.

7.

The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro.

Chen MC, Zhou B, Zhang K, Yuan YC, Un F, Hu S, Chou CM, Chen CH, Wu J, Wang Y, Liu X, Smith DL, Li H, Liu Z, Warden CD, Su L, Malkas LH, Chung YM, Hu MC, Yen Y.

Mol Pharmacol. 2015 Jun;87(6):996-1005. doi: 10.1124/mol.114.094987. Epub 2015 Mar 26.

8.

Human C6orf211 encodes Armt1, a protein carboxyl methyltransferase that targets PCNA and is linked to the DNA damage response.

Perry JJ, Ballard GD, Albert AE, Dobrolecki LE, Malkas LH, Hoelz DJ.

Cell Rep. 2015 Mar 3;10(8):1288-96. doi: 10.1016/j.celrep.2015.01.054. Epub 2015 Feb 26.

9.

A Peptide mimicking a region in proliferating cell nuclear antigen specific to key protein interactions is cytotoxic to breast cancer.

Smith SJ, Gu L, Phipps EA, Dobrolecki LE, Mabrey KS, Gulley P, Dillehay KL, Dong Z, Fields GB, Chen YR, Ann D, Hickey RJ, Malkas LH.

Mol Pharmacol. 2015 Feb;87(2):263-76. doi: 10.1124/mol.114.093211. Epub 2014 Dec 5.

10.

Expression of a novel peptide derived from PCNA damages DNA and reverses cisplatin resistance.

Lingeman RG, Hickey RJ, Malkas LH.

Cancer Chemother Pharmacol. 2014 Nov;74(5):981-93. doi: 10.1007/s00280-014-2574-x. Epub 2014 Sep 5.

11.

A novel berbamine derivative inhibits cell viability and induces apoptosis in cancer stem-like cells of human glioblastoma, via up-regulation of miRNA-4284 and JNK/AP-1 signaling.

Yang F, Nam S, Brown CE, Zhao R, Starr R, Ma Y, Xie J, Horne DA, Malkas LH, Jove R, Hickey RJ.

PLoS One. 2014 Apr 14;9(4):e94443. doi: 10.1371/journal.pone.0094443. eCollection 2014. Erratum in: PLoS One. 2014;9(6):e100708. Ma, Yuelong [added]; Xie, Jun [added].

12.

A PCNA-derived cell permeable peptide selectively inhibits neuroblastoma cell growth.

Gu L, Smith S, Li C, Hickey RJ, Stark JM, Fields GB, Lang WH, Sandoval JA, Malkas LH.

PLoS One. 2014 Apr 11;9(4):e94773. doi: 10.1371/journal.pone.0094773. eCollection 2014.

13.

Error-promoting DNA synthesis in ovarian cancer cells.

Dai H, Hickey RJ, Liu J, Bigsby RM, Lanner C, Malkas LH.

Gynecol Oncol. 2013 Oct;131(1):198-206. doi: 10.1016/j.ygyno.2013.06.022. Epub 2013 Jul 12.

14.

Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical Integration.

Loh AH, Brennan RC, Lang WH, Hickey RJ, Malkas LH, Sandoval JA.

Front Oncol. 2013 Apr 23;3:93. doi: 10.3389/fonc.2013.00093. eCollection 2013.

15.

Small-molecule targeting of proliferating cell nuclear antigen chromatin association inhibits tumor cell growth.

Tan Z, Wortman M, Dillehay KL, Seibel WL, Evelyn CR, Smith SJ, Malkas LH, Zheng Y, Lu S, Dong Z.

Mol Pharmacol. 2012 Jun;81(6):811-9. doi: 10.1124/mol.112.077735. Epub 2012 Mar 7.

16.

Clinical significance of serum biomarkers in pediatric solid mediastinal and abdominal tumors.

Sandoval JA, Malkas LH, Hickey RJ.

Int J Mol Sci. 2012;13(1):1126-53. doi: 10.3390/ijms13011126. Epub 2012 Jan 20. Review.

17.

Phosphorylation: the molecular switch of double-strand break repair.

Summers KC, Shen F, Sierra Potchanant EA, Phipps EA, Hickey RJ, Malkas LH.

Int J Proteomics. 2011;2011:373816. doi: 10.1155/2011/373816. Epub 2011 May 18.

18.

Nuclear protein isoforms: implications for cancer diagnosis and therapy.

Shen F, Kirmani KZ, Xiao Z, Thirlby BH, Hickey RJ, Malkas LH.

J Cell Biochem. 2011 Mar;112(3):756-60. doi: 10.1002/jcb.23002. Review.

19.

Elevated expression of cancer-associated proliferating cell nuclear antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer.

Wang X, Hickey RJ, Malkas LH, Koch MO, Li L, Zhang S, Sandusky GE, Grignon DJ, Eble JN, Cheng L.

Prostate. 2011 May 15;71(7):748-54. doi: 10.1002/pros.21291. Epub 2010 Oct 28.

20.

Proteomic approaches in neuroblastoma: a complementary clinical platform for the future.

Kumar HR, Zhong X, Rescorla FJ, Hickey RJ, Malkas LH, Sandoval JA.

Expert Rev Proteomics. 2009 Aug;6(4):387-94. doi: 10.1586/epr.09.58. Review.

PMID:
19681674
21.

Proteomic analysis of neuroblastoma microenvironment: effect of the host-tumor interaction on disease progression.

Turner KE, Kumar HR, Hoelz DJ, Zhong X, Rescorla FJ, Hickey RJ, Malkas LH, Sandoval JA.

J Surg Res. 2009 Sep;156(1):116-22. doi: 10.1016/j.jss.2009.02.019. Epub 2009 Mar 25.

PMID:
19592021
22.

Bin1 is linked to metastatic potential and chemosensitivity in neuroblastoma.

Zhong X, Hoelz DJ, Kumar HR, Sandoval JA, Rescorla FJ, Hickey RJ, Malkas LH.

Pediatr Blood Cancer. 2009 Sep;53(3):332-7. doi: 10.1002/pbc.22068.

PMID:
19418541
23.

Chromium reduces the in vitro activity and fidelity of DNA replication mediated by the human cell DNA synthesome.

Dai H, Liu J, Malkas LH, Catalano J, Alagharu S, Hickey RJ.

Toxicol Appl Pharmacol. 2009 Apr 15;236(2):154-65. doi: 10.1016/j.taap.2008.12.028. Epub 2009 Jan 23.

24.

Characterization of RNA primers synthesized by the human breast cancer cell DNA synthesome.

Dai H, Liu J, Malkas LH, Hickey RJ.

J Cell Biochem. 2009 Apr 1;106(5):798-811. doi: 10.1002/jcb.22015.

25.

Applications of emerging molecular technologies in glioblastoma multiforme.

Kumar HR, Zhong X, Sandoval JA, Hickey RJ, Malkas LH.

Expert Rev Neurother. 2008 Oct;8(10):1497-506. doi: 10.1586/14737175.8.10.1497. Review.

26.

Three-dimensional neuroblastoma cell culture: proteomic analysis between monolayer and multicellular tumor spheroids.

Kumar HR, Zhong X, Hoelz DJ, Rescorla FJ, Hickey RJ, Malkas LH, Sandoval JA.

Pediatr Surg Int. 2008 Nov;24(11):1229-34. doi: 10.1007/s00383-008-2245-2. Epub 2008 Sep 17.

27.

Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles.

Kyselova Z, Mechref Y, Kang P, Goetz JA, Dobrolecki LE, Sledge GW, Schnaper L, Hickey RJ, Malkas LH, Novotny MV.

Clin Chem. 2008 Jul;54(7):1166-75. doi: 10.1373/clinchem.2007.087148. Epub 2008 May 16.

28.

Oxidative status in neuroblastoma: a source of stress?

Novotny NM, Grosfeld JL, Turner KE, Rescorla FJ, Pu X, Klaunig JE, Hickey RJ, Malkas LH, Sandoval JA.

J Pediatr Surg. 2008 Feb;43(2):330-4. doi: 10.1016/j.jpedsurg.2007.10.040.

29.

Serum protein profiling to identify high-risk neuroblastoma: preclinical relevance of blood-based biomarkers.

Sandoval JA, Turner KE, Hoelz DJ, Rescorla FJ, Hickey RJ, Malkas LH.

J Surg Res. 2007 Oct;142(2):268-74. Epub 2007 Aug 29.

30.

Diagnosis of esophageal adenocarcinoma by serum proteomic pattern.

Hammoud ZT, Dobrolecki L, Kesler KA, Rahmani E, Rieger K, Malkas LH, Hickey RJ.

Ann Thorac Surg. 2007 Aug;84(2):384-92; discussion 392.

PMID:
17643604
31.

A novel biomarker for the detection of esophageal adenocarcinoma.

Hammoud ZT, Badve S, Saxena R, Kesler KA, Rieger K, Malkas LH, Hickey RJ.

J Thorac Cardiovasc Surg. 2007 Jan;133(1):82-7. Epub 2006 Dec 4.

32.

A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker.

Malkas LH, Herbert BS, Abdel-Aziz W, Dobrolecki LE, Liu Y, Agarwal B, Hoelz D, Badve S, Schnaper L, Arnold RJ, Mechref Y, Novotny MV, Loehrer P, Goulet RJ, Hickey RJ.

Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19472-7. Epub 2006 Dec 11.

33.

The discovery of labile methyl esters on proliferating cell nuclear antigen by MS/MS.

Hoelz DJ, Arnold RJ, Dobrolecki LE, Abdel-Aziz W, Loehrer AP, Novotny MV, Schnaper L, Hickey RJ, Malkas LH.

Proteomics. 2006 Sep;6(17):4808-16.

PMID:
16888766
34.

Proteomic analysis of neuroblastoma subtypes in response to mitogen-activated protein kinase inhibition: profiling multiple targets of cancer kinase signaling.

Sandoval JA, Eppstein AC, Hoelz DJ, Klein PJ, Linebarger JH, Turner KE, Rescorla FJ, Hickey RJ, Malkas LH, Schmidt CM.

J Surg Res. 2006 Jul;134(1):61-7. Epub 2006 May 2.

PMID:
16650873
35.

Neuroblastoma detection using serum proteomic profiling: a novel mining technique for cancer?

Sandoval JA, Dobrolecki LE, Huang J, Grosfeld JL, Hickey RJ, Malkas LH.

J Pediatr Surg. 2006 Apr;41(4):639-46; discussion 639-46.

PMID:
16567169
36.

Structural analysis of the human neuroblastoma DNA replication complex: insights into faulty proliferation.

Sandoval JA, Grosfeld JL, Hickey RJ, Malkas LH.

J Pediatr Surg. 2006 Jan;41(1):266-70.

PMID:
16410145
37.

Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126.

Eppstein AC, Sandoval JA, Klein PJ, Woodruff HA, Grosfeld JL, Hickey RJ, Malkas LH, Schmidt CM.

J Pediatr Surg. 2006 Jan;41(1):252-9.

PMID:
16410143
38.

Novel peptides secreted from human neuroblastoma: useful clinical tools?

Sandoval JA, Hoelz DJ, Woodruff HA, Powell RL, Jay CL, Grosfeld JL, Hickeyd RJ, Malkas LH.

J Pediatr Surg. 2006 Jan;41(1):245-51.

PMID:
16410142
39.

DNA damage-induced phosphorylation of the human telomere-associated protein TRF2.

Tanaka H, Mendonca MS, Bradshaw PS, Hoelz DJ, Malkas LH, Meyn MS, Gilley D.

Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15539-44. Epub 2005 Oct 13.

40.

Isolation and characterization of a DNA synthesome from a neuroblastoma cell line.

Sandoval JA, Hickey RJ, Malkas LH.

J Pediatr Surg. 2005 Jul;40(7):1070-7.

PMID:
16034747
41.

Profiling of nuclear extract proteins from human neuroblastoma cell lines: the search for fingerprints.

Escobar MA, Hoelz DJ, Sandoval JA, Hickey RJ, Grosfeld JL, Malkas LH.

J Pediatr Surg. 2005 Feb;40(2):349-58.

PMID:
15750928
42.
43.

An in vitro model system that can differentiate the stages of DNA replication affected by anticancer agents.

Abdel-Aziz W, Hickey RJ, Malkas LH.

Biochem Pharmacol. 2004 Jul 1;68(1):11-21.

PMID:
15183113
44.

Effect of novel benzoylphenylurea derivatives on DNA polymerase alpha activity using the synthesome-based in vitro model system.

Abdel-Aziz W, Hickey R, Edelman M, Malkas L.

Invest New Drugs. 2003 Nov;21(4):421-8.

PMID:
14586209
45.

The DNA synthesome: its potential as a novel in vitro model system for studying S-phase specific anticancer agents.

Abdel-Aziz W, Malkas LH, Wills PW, Hickey RJ.

Crit Rev Oncol Hematol. 2003 Oct;48(1):19-33. Review.

PMID:
14585481
46.

DNMT1 is a component of a multiprotein DNA replication complex.

Vertino PM, Sekowski JA, Coll JM, Applegren N, Han S, Hickey RJ, Malkas LH.

Cell Cycle. 2002 Nov-Dec;1(6):416-23.

PMID:
12548018
47.

Synthesis and preliminary pharmacological evaluation of new (+/-) 1,4-naphthoquinones structurally related to lapachol.

da Silva AJ, Buarque CD, Brito FV, Aurelian L, Macedo LF, Malkas LH, Hickey RJ, Lopes DV, Noël F, Murakami YL, Silva NM, Melo PA, Caruso RR, Castro NG, Costa PR.

Bioorg Med Chem. 2002 Aug;10(8):2731-8.

PMID:
12057662
48.

Human cell DNA replication is mediated by a discrete multiprotein complex.

Jiang HY, Hickey RJ, Abdel-Aziz W, Tom TD, Wills PW, Liu J, Malkas LH.

J Cell Biochem. 2002;85(4):762-74.

PMID:
11968016
49.

Smad 3 may regulate follicular growth in the mouse ovary.

Tomic D, Brodie SG, Deng C, Hickey RJ, Babus JK, Malkas LH, Flaws JA.

Biol Reprod. 2002 Apr;66(4):917-23.

PMID:
11906909
50.

Effects of gemcitabine and araC on in vitro DNA synthesis mediated by the human breast cell DNA synthesome.

Jiang HY, Hickey RJ, Abdel-Aziz W, Malkas LH.

Cancer Chemother Pharmacol. 2000;45(4):320-8.

PMID:
10755321

Supplemental Content

Loading ...
Support Center